Profile data is unavailable for this security.
About the company
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
- Revenue in USD (TTM)6.85m
- Net income in USD-138.42m
- Incorporated2020
- Employees77.00
- LocationCentessa Pharmaceuticals PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
- Websitehttps://www.centessa.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunome Inc | 12.68m | -232.03m | 895.93m | 55.00 | -- | 3.12 | -- | 70.64 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
USANA Health Sciences, Inc. | 900.45m | 61.94m | 906.81m | 1.80k | 14.86 | 1.81 | 12.17 | 1.01 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
Nurix Therapeutics Inc | 80.89m | -144.73m | 934.03m | 284.00 | -- | 4.59 | -- | 11.55 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
OPKO Health Inc | 799.60m | -252.43m | 954.88m | 3.93k | -- | 0.7622 | -- | 1.19 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 967.79m | 296.00 | -- | 4.29 | -- | 9.10 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Gyre Therapeutics Inc | 140.62m | -85.66m | 971.39m | 593.00 | -- | 17.13 | -- | 6.91 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
Centessa Pharmaceuticals PLC - ADR | 6.85m | -138.42m | 975.57m | 77.00 | -- | 4.03 | -- | 142.36 | -1.42 | -1.42 | 0.0704 | 2.14 | 0.0187 | -- | 0.2263 | 90,171.05 | -37.82 | -- | -41.02 | -- | -- | -- | -2,019.80 | -- | -- | -- | 0.263 | -- | -- | -- | 30.12 | -- | -- | -- |
Silence Therapeutics plc | 33.64m | -44.51m | 979.39m | 115.00 | -- | 6.72 | -- | 29.11 | -0.3911 | -0.3911 | 0.2856 | 1.13 | 0.1829 | -- | 5.37 | 292,521.00 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Liquidia Corp | 15.97m | -107.69m | 983.05m | 136.00 | -- | 11.38 | -- | 61.57 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
Innoviva Inc | 311.59m | 181.39m | 986.00m | 112.00 | 7.21 | 1.41 | 4.49 | 3.16 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.00bn | 267.00 | -- | -- | -- | 2.42 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Pharvaris NV | 0.00 | -115.20m | 1.02bn | 82.00 | -- | 2.62 | -- | -- | -2.58 | -2.58 | 0.00 | 7.24 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 1.05bn | 180.00 | -- | 3.96 | -- | 8.39 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Cassava Sciences Inc | 0.00 | -47.90m | 1.06bn | 29.00 | -- | 12.12 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 5.62m | 5.60% |
Perceptive Advisors LLCas of 31 Mar 2024 | 3.08m | 3.07% |
First Light Asset Management LLCas of 31 Mar 2024 | 3.00m | 2.99% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.96m | 2.95% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.79m | 2.78% |
Point72 Asset Management LPas of 31 Mar 2024 | 2.26m | 2.25% |
Adage Capital Management LPas of 31 Mar 2024 | 2.25m | 2.24% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.13m | 2.13% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 2.06m | 2.05% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 1.41m | 1.41% |